Egis Pharmaceuticals made a net profit of CZK HUF 18,531 mil under revenues of HUF 132,825 mil in 2012, up 36.4% and 3.01%, respectively, when compared to the last year.
This translates into a net margin of 14.0%. Historically, the firm’s net margin reached an all time high of 15.2% in 2006 and an all time low of 6.50% in 2007. The average net margin in the last five years amounted to 12.3%.
On the operating level, EBITDA margin reached 15.4% and EBIT amounted to 23.0% of sales in 2012.
As far as Egis Pharmaceuticals's peers are concerned, Gedeon Richter posted net and EBITDA margin of 15.1% and 23.1%, respectively in 2012, Krka generated margins of 14.0% and 24.5% and Sanofi-Aventis Czech Republic's profit margin reached 0.626% on the net and 1.12% on the EBITDA level in 2012.